Compare CDMOs manufacturing oral solid dosage forms -- tablets, capsules, and modified-release products. Filter by batch size, coating technology, and regulatory approvals.
373 companies listed
Oral solid dose (OSD) is the most common pharmaceutical dosage form, accounting for approximately 60% of all drug products. Manufacturing involves blending, granulation (wet or dry), compression or encapsulation, film coating, and packaging. CDMOs range from small clinical-batch operations to high-throughput commercial manufacturers producing millions of units daily.
Modified-release technologies differentiate advanced OSD CDMOs. Extended-release, delayed-release, and pulsatile-release formulations improve patient compliance and can extend product lifecycle. Technologies include matrix tablets, osmotic systems, multiparticulate systems (coated pellets in capsules), and multi-layer tablets for combination products.
Scale is a key selection criterion. Clinical-phase OSD often runs in batches of 5,000-50,000 units. Commercial scale may mean 500,000+ units per batch. Equipment compatibility (granulators, presses, coaters) must match your projected volumes. Ask about batch success rates and changeover times between products.
United States
UPM Pharmaceuticals is a U.S.-based CDMO specializing in late-stage commercial manufacturing of semi-solid and oral solid dose products. Operating from a 475,000 sq ft cGMP FDA-registered facility in Bristol, Tennessee, UPM is a family-owned company with 30+ years of experience. They handle DEA-controlled substances and provide services from technology transfer and scale-up through commercial manufacturing. Capabilities include formulation development, analytical development, coated tablet manufacturing, pharmaceutical serialization, aggregation, and full packaging and warehousing.
Canada
ResolveMass Laboratories Inc. is a Canadian pharmaceutical CRO and CDMO providing analytical testing, characterization, and drug development support for pharmaceutical, biotechnology, and medical device companies worldwide. Our expertise spans small molecules, peptides, biologics, biosimilars, oligonucleotides, polymers, and complex drug products. We offer specialized services including mass spectrometry (LC-MS/MS, LC-HRMS), peptide characterization, impurity identification, nitrosamine analysis, extractables and leachables (E&L) studies, bioanalytical testing, stability studies, method development, and regulatory support. Our multidisciplinary scientific team helps clients address complex analytical challenges and generate high-quality data to support research, development, manufacturing, and regulatory submissions. ResolveMass Laboratories operates from Canada and serves clients across North America, Europe, and Asia. The company maintains an ISO 9001:2015 certified Quality Management System, is FDA-registered, and holds a Health Canada Drug Establishment Licence for GMP-compliant operations. We are committed to delivering scientifically rigorous, reliable, and timely solutions that accelerate drug development and support regulatory success.
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.